Phase 3 trial results bring hope for patients with IgA nephropathy

Lancet. 2023 Sep 9;402(10405):827-829. doi: 10.1016/S0140-6736(23)01633-1. Epub 2023 Aug 14.

Author

Börje Haraldsson¹

Affiliation

¹ Institute of Neuroscience and Physiology, University of Gothenburg, 405 30 Gothenburg, Sweden. Electronic address: borje.haraldsson@gu.se.

PMID: 37591290
DOI: 10.1016/S0140-6736(23)01633-1

No abstract available

Publication types

Clinical Trial, Phase III
Comment

MeSH terms

Glomerulonephritis, IGA* / therapy
Humans
Patients